iv Iron in Heart Failure - Prof. Robert Mentz, Prof. Hossein Ardehali, Prof. Paul Kalra

After publication of the large phase 3 IRONMAN and HEART-FID studies, Prof. Robert Mentz (Durham, NC, USA), Prof. Hossein Ardehali (Chicago, IL, USA) and Prof. Paul Kalra (Portsmouth, UK) discuss the prognostic implication of intravenous iron supplementation in patients with heart failure.
Dr Paul Kalra is Professor of Cardiology at Portsmouth Hospitals NHS Trust, UK; his major sub-specialty interest is the assessment and management of patients with heart failure. He has been the elected Chair of the British Society for Heart Failure between 2017 and 2019, and he is the Chief Investigator of IRONMAN study funded by the British Heart Foundation on the prognostic implication of iv iron in heart failure patients.
Dr. Robert Mentz is Cardiologist and Associate Professor of Medicine, Associate Professor in Population Health Sciences and Member in the Duke Clinical Research Institute in the Department of Medicine of Duke University School of Medicine in Durham, NC. A major focus of Dr. Mentz' clinical and research work is heart failure, including advanced therapies such as cardiac transplantation and mechanical assist devices. He is the Principle Investigator of HEART-FID, which also tested the prognostic implications of iv iron in heart failure, using here an alternative iv iron compound compared to IRONMAN.
Dr. Hossein Ardehali is Cardiologist and Professor of Medicine at Northwestern University Feinberg School of Medicine, Chicago, IL, and director of the Feinberg Cardiovascular and Renal Research Institute’s Center for Molecular Cardiology. He has published pivotal basic research studies on the benefits and risks of iron on cellular and subcellular levels, and he has written several clinical reviews and editorials that caution against a too broad application of iv iron in heart failure for the time being.
The interview was recorded on September 13th, 2023.
Moderators: Prof. Dr. Marcus Säemann (Vienna, Austria), Prof. Dr. Florian Custodis (Saarbrücken, Germany) and Prof. Dr. Gunnar Heine (Frankfurt, Germany).
Articles discussed:
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.
Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I; IRONMAN Study Group.
Lancet. 2022
doi: 10.1016/S0140-6736(22)02083-9
Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, Lewis GD, O'Meara E, Ponikowski P, Troughton RW, Wong YW, She L, Harrington J, Adamczyk R, Blackman N, Hernandez AF; HEART-FID Investigators.
N Engl J Med. 2023
doi: 10.1056/NEJMoa2304968
Potential Interactions When Prescribing SGLT2 Inhibitors and Intravenous Iron in Combination in Heart Failure.
Packer M.
JACC Heart Fail. 2023
doi: 10.1016/j.jchf.2022.10.004
Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial.
Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, Tang WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, Van Buren P, Whellan D, Anstrom KJ, Shah MR, Desvigne-Nickens P, Butler J, Braunwald E; NHLBI Heart Failure Clinical Research Network.
JAMA. 2017
doi: 10.1001/jama.2017.5427